What does purchases of fixed maturity securities mean?

Cash spent purchasing fixed-income securities (bonds, notes, debentures) for the investment portfolio.

Castle Biosciences CSTL Purchases of fixed maturity securities

Purchases of fixed maturity securities at other companies

VeracyteVCYT

$125M+150%

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's purchases of fixed maturity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's purchases of fixed maturity securities?: Castle Biosciences (CSTL) reported purchases of fixed maturity securities of $0 in Q1 2026.
How has Castle Biosciences's purchases of fixed maturity securities changed year-over-year?: Castle Biosciences's purchases of fixed maturity securities decreased by 100.0% year-over-year, from $5.57M to $0.
What does purchases of fixed maturity securities mean?: Cash spent purchasing fixed-income securities (bonds, notes, debentures) for the investment portfolio.